Patent Awarded for Pancreatic Enzyme Therapy for ADD, ADHD and Autism

The U.S. Patent and Trademark office has awarded Dr. Joan Fallon patent # 6,632,429 entitled Methods for Treating Pervasive Developmental Disorders.The patent covers the use of digestive and pancreatic enzymes as a treatment for children with ADD, ADHD and Autism. Dr. Fallon's invention employs the use of digestive and pancreatic enzymes for children with these conditions based upon the presence of a low level of chymotrypsin in the stool.

The U.S. Patent and Trademark office has awarded Dr. Joan Fallon patent # 6,632,429 entitled Methods for Treating Pervasive Developmental Disorders. The patent covers the use of digestive and pancreatic enzymes as a treatment for children with ADD, ADHD and Autism.

The patent, which will remain in effect until 2019, represents a breakthrough for children with pervasive developmental disorders including ADD, ADHD and Autism. Autism is characterized by profound delays in communication and social interaction and is thought to affect over 1.5 million individuals in the U.S.

ADD and ADHD have a prevalence of between 5 and 10% in the population. It is estimated that upwards of 10% of the population is medicated for some type of attention disorder.

Dr. Fallon's invention employs the use of digestive and pancreatic enzymes for children with these conditions based upon the presence of a low level of chymotrypsin in the stool. Chymotrypsin is an enzyme secreted by the pancreas in an inactive form which becomes active in the presence of protein in the small intestines as well as a favorable pH. Without sufficient protein digestion, the formation of amino acids, the building blocks of new proteins, cannot occur. The lack of protein synthesis can underlie a significant neurological deficit in the child. Fallon's patent demonstrates that the administration of digestive and pancreatic enzymes produce profound changes in the autistic symptomotology including increases in social interactions, eye contact and speech and reductions in repetitive actions and hyperactivity. It further demonstrates changes in bowel habits including an increase in bowel control and formed movements.

In the child with ADD and ADHD, the therapy significantly reduces the levels of medication the child is taking and, in many cases, the child no longer needs the medication, based upon observed increases in attention.

"The patent recognizes a deficiency in the children with ADD, ADHD and Autism, and offers a biological solution. Digestive and pancreatic enzymes have been used safely and effectively for children and adults with cystic fibrosis for many years," said Dr. Fallon, inventor and patent holder. "I intend to continue to refine the use of digestive and pancreatic enzymes for these and other indications. This form of treatment opens new avenues for children and adults with these debilitating conditions.

Contact: Dr. Joan Fallon 914-779-9300 joanfallon@aol.com